Clinical Core

$626,553P50FY2015NSNIH

University Of Washington, Seattle WA

Investigators

Linked publications & trials

Paper 39557903 Paper 39399688 Paper 39314957 Paper 38888142 Paper 38870440 Paper 38853953 Paper 38436140 Paper 37972450 Paper 37964373 Paper 37279935 Paper 37252677 Paper 37010072 Paper 36511519 Paper 36394592 Paper 35808984 Paper 35779041 Paper 35448464 Paper 35357463 Paper 35121993 Paper 35099792 Paper 35093191 Paper 34961556 Paper 34910503 Paper 34408160 Paper 34382643 Paper 34355669 Paper 34310044 Paper 34032594 Paper 33938021 Paper 33818911 Paper 33646154 Paper 33584497 Paper 33579999 Paper 33497263 Paper 33484978 Paper 33298513 Paper 33292899 Paper 33252618 Paper 33239300 Paper 33180719 Paper 33106633 Paper 33013627 Paper 33000167 Paper 32961131 Paper 32937003 Paper 32885039 Paper 32775508 Paper 32741842 Paper 32641150 Paper 32620863 Paper 32566740 Paper 32559629 Paper 32139977 Paper 32065223 Paper 31970213 Paper 31941827 Paper 31731260 Paper 31633026 Paper 31629653 Paper 31403079 Paper 31392412 Paper 31362787 Paper 31177941 Paper 31131605 Paper 30958379 Paper 30924200 Paper 30909225 Paper 30826425 Paper 30796007 Paper 30776152 Paper 30685501 Paper 30660957 Paper 30584162 Paper 30465796 Paper 30452409 Paper 30216541 Paper 30056417 Paper 30052535 Paper 29892607 Paper 29793507 Paper 29572994 Paper 29486463 Paper 29478836 Paper 29478701 Paper 29456161 Paper 29311311 Paper 29163119 Paper 28846090 Paper 28807493 Paper 28699334 Paper 28644039 Paper 28594877 Paper 28538087 Paper 28526295 Paper 28453469 Paper 28336296 Paper 28319654 Paper 28270762 Paper 28268100 Paper 28215728

Abstract

CLINICAL CORE: ABSTRACT The Pacific Northwest Udall Center (PANUC) Clinical Core has recruited and characterized a cohort of more than 600 individuals with Parkinson's disease (PD) during the inaugural award. Data from the PANUC Clinical Core, in collaboration with other Udall Centers and other academic medical centers, have helped confirm Apolipoprotein E (APOE) and glucocerebrosidase (GBA) as genes that are relevant to the pathogenesis of cognitive decline in PD. Understanding the mechanisms underlying these gene effects is the focus of this renewal application, utilizing brain autopsy and genomic approaches (Project 1), neuroimaging (Project 2), and quantitative balance and gait (B&G) measurements (Project 3). The Clinical Core will provide longitudinal data for subjects in all 3 projects, and will provide well-characterized PD and control subjects of appropriate genotypes for Projects 2 and 3. B&G testing has been added to the test battery as an innovation that is thought to reflect higher order CNS function closely related to cognition. This innovation leverages the expertise of Dr. Fay Horak, an investigator introduced to PANUC by way of PANUC pilot award funding. As in the first cycle, Clinical Core subjects will be followed at two sites: one in Portland directed by Clinical Core Leader Dr. Joseph Quinn, and the other in Seattle directed by Clinical Core Co-Leader Dr. Shu-Ching Hu.

View original record on NIH RePORTER →